Six COVID-19 vaccines are safe and boost immunity for people who have had two doses of AstraZeneca or Pfizer-BioNTech. This is according to results from the UK-wide COV-BOOST trial.

The world-first study recruited volunteers at Guy’s and St Thomas’ NHS Foundation Trust. It was key to shaping the UK booster programme and gives vital evidence for global vaccination efforts. The study was led by University Hospital Southampton. These latest results were published in the journal the Lancet.

COV-BOOST looked at the safety, immune responses and side-effects of seven vaccines when used as a third, booster jab. Around 200 volunteers joined the study at the Trust.

Run at 18 National Institute for Health Research-supported sites, the study saw 2,878 people aged 30 or over recruited. Participants received a booster 10-12 weeks after their initial two-dose vaccination with either AstraZeneca or Pfizer-BioNTech. A control group was given a meningitis vaccine, to account for reactions not specific to the COVID-19 jabs.

The seven vaccines trialled were:

  • AstraZeneca-Oxford
  • Pfizer-BioNTech
  • Moderna
  • Novavax
  • Valneva
  • Janssen
  • CureVac

Of these, only AstraZeneca, Pfizer-BioNTech, Moderna and Janssen are currently licensed for use in the UK. Half-doses of Pfizer-BioNtech, Novavax and Valneva were also tested.

Anna Goodman, consultant in infectious diseases at Guy’s and St Thomas’, was the local principal investigator for the study. She said: “We are incredibly grateful to the participants who took part in the study at our Trust and throughout the country.

“These findings are really positive as they build on our range of available vaccines to ensure in the future we have many different vaccines available. They show that a range of vaccines can improve the immune responses when given as boosters following COVID-19 vaccination. The fact that most were shown to improve antibody levels is wonderful news. It is important that anyone who is eligible takes up the offer of a booster to help protect themselves and their loved ones from COVID-19.”

Professor Saul Faust, trial lead and Director of the NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust (UHS), said: “Our side effect data shows all seven vaccines are safe to use as a third dose, with acceptable levels of ‘reactogenicity’ – inflammatory side effects like injection site pain, muscle soreness, fatigue. All seven boosted levels of spike protein antibodies significantly after two doses of AstraZeneca. However only six also did so after two doses of Pfizer-BioNTech (AstraZeneca, Pfizer-BioNTech, Moderna, Novavax, Janssen and CureVac). There were also large variations in response with different boosters.

“It’s really encouraging that a wide range of vaccines, using different technologies, show benefits as a booster dose to either of these vaccines. That gives confidence and flexibility in developing booster programmes here and globally, with other factors like supply chain and logistics also in play.”

There were large differences in levels of antibodies after 28 days across the vaccines.

The trial measured the response in people who had received two initial doses of AstraZeneca, but received different booster vaccines. This response ranged from 1.8 times higher to 32.3 times higher, depending on the booster given.

The team also looked at those who had received Pfizer-BioNTech initially. For these, the range was 1.3 times higher to 11.5 times higher with different boosters.

Booster results were similar for those aged 30-69 years and those aged 70 years or older.Reactions to all seven vaccines were similar. Fatigue, headache, and injection site pain were the side effects most often reported. These were more commonly reported by those aged 30-69. Of the 2,878 participants, 912 experienced adverse events. Of the 1036 events reported, only 24 were severe.

Prof Faust added: “It’s important to note two things about these results. First, they only relate to these vaccines as boosters to the two primary vaccinations, not how well they work as first and second doses. Secondly, the data describe the immune response at 28 days, not vaccine effectiveness. The relationship between that response and long-term protection is still poorly understood. We will be looking at the longer-term immune responses in COV-BOOST, conducting further tests at three months and one year after receiving boosters.

“We are also looking at whether a longer period between second and third doses improves response to the booster vaccines. Several studies have shown this effect between first and second doses. We’ve done that by giving some of our original control participants the booster at a later point, and we expect those results to be available in the new year.”

Professor Andrew Ustianowski, National Clinical Lead for the UK NIHR COVID Vaccine Research Programme said: “Heading into the winter, and due to the emergence of the Omicron, the results from the COV-BOOST study are extremely timely and of national and international importance.

“Since the beginning of the pandemic the National Institute for Health Research and the NHS have been supported by the efforts and selflessness of study participants – helping us to identify the most effective vaccines and how they can be used flexibly to protect more people.

“We welcome the latest results from the study, and continue to support the COV-BOOST team with the further analysis of data which will help us understand the use of these vaccines as boosters long term.”

COV-BOOST was designed so that stored samples can used in evaluating these vaccines’ effectiveness in neutralising any new variants of concern. COV-BOOST samples have been made available to UK Health Security Agency for testing against omicron.